Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.
Neuroleptic malignant syndrome (NMS) is a rare, but potentially lethal complication of antipsychotic medication. The risk of developing NMS under atypical neuroleptics seems lower than under typical neuroleptics. However, the use of atypical neuroleptics in modern psychopharmacotherapy is increasing, so the incidence of NMS under these drugs may also increase. Here, we will describe three episodes of NMS that fulfilled the DSM-IV criteria for NMS (APA, 1994). The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride. These episodes had some atypical features that will be discussed with regard to the pathophysiological mechanisms leading to NMS.
Bottlender
R
R
Department of Psychiatry, Ludwig-Maximilians-University, Munich. bottlend@psy.med.uni-muenchen.de
Jäger
M
M
Hofschuster
E
E
Dobmeier
P
P
Möller
H-J
HJ
D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003024:Clozapine / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology* / Q000503:physiopathology; D018967:Risperidone / Q000009:adverse effects; D012559:Schizophrenia / Q000188:drug therapy; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives*
D014150:Antipsychotic Agents; D013469:Sulpiride; D000077582:Amisulpride; D003024:Clozapine; D018967:Risperidone